Complement C5a is present in CSF of human newborns and is elevated in association with preterm birth

Citation for published version:
Pataky, R, Howie, AF, Girardi, G & Boardman, J 2016, 'Complement C5a is present in CSF of human newborns and is elevated in association with preterm birth' Journal of Maternal-Fetal and Neonatal Medicine. DOI: 10.1080/14767058.2016.1251896

Digital Object Identifier (DOI):
10.1080/14767058.2016.1251896

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Maternal-Fetal and Neonatal Medicine

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Complement C5a is present in CSF of human newborns and is elevated in association with preterm birth

Rozalia Pataky, Forbes A. Howie, Guillermina Girardi & James P. Boardman

To cite this article: Rozalia Pataky, Forbes A. Howie, Guillermina Girardi & James P. Boardman (2016): Complement C5a is present in CSF of human newborns and is elevated in association with preterm birth, The Journal of Maternal-Fetal & Neonatal Medicine, DOI: 10.1080/14767058.2016.1251896

To link to this article: http://dx.doi.org/10.1080/14767058.2016.1251896
Complement C5a is present in CSF of human newborns and is elevated in association with preterm birth

Rozalia Pataky1, Forbes A. Howie1, Guillermina Girardi2*, and James P. Boardman1*

1MRC Centre for Reproductive Health, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK and 2Department of Women’s Health, King’s College London, St Thomas’ Hospital, London, UK

Abstract
Neuroinflammation contributes to developmental brain injury associated with preterm birth, but the mediators that drive it are incompletely understood. Previous studies have shown that complement C5a is present and injurious in the brains of foetal mice exposed to preterm labour. Here, we demonstrate that C5a is present in the cerebrospinal fluid of newborn human infants and that levels are elevated in those born preterm. The difference is not explained by systemic infection. Complement activation in the neonatal brain and its role as a potential therapeutic target in preterm brain injury warrant further study.

Keywords
Preterm infant, brain, neuroinflammation, complement system, C5a

Introduction
Preterm birth is strongly associated with a phenotype that includes brain injury and long-term neurodevelopmental and psychiatric impairments. Inflammation is a major contributor to injury but the mediators and receptors involved are uncertain [1].

The complement system is part of the innate immune response to tissue injury and infection. Its four pathways all result in the production of C5a, a potent anaphylatoxin that binds to receptor C5aR to induce a range of inflammatory activities. C5aR is widely expressed in the human central nervous system [2], including in early development [3,4], and C5a-C5aR signalling is implicated in the pathogenesis of neurodegenerative and inflammatory CNS diseases in experimental models [2]. In a mouse model of inflammation-induced preterm birth C5a contributes to cortical neuronal injury in utero, mediated through glutamate excitotoxicity [5]. Importantly, in this model, neuronal protection was achieved through C5aR blockade, which raises the possibility that modifying the complement system could be an effective neuroprotective strategy. There are limited data on C5a in human CNS disease and its role in developmental brain injury is unknown. We aimed to determine whether C5a is present in the cerebrospinal fluid (CSF) of newborns, and hypothesised that levels would be increased among those born preterm.

Materials and methods
Participants
We recruited two groups of neonates from the Royal Infirmary of Edinburgh between June 2014 and September 2015 who required CSF sampling, usually for the evaluation of suspected sepsis: (1) preterm neonates (<32 weeks’ gestation); and control infants born at >37 weeks’ gestation.

Written parental informed consent was obtained, and the study was approved by the UK National Research Ethics Service.

CSF samples
Lumbar puncture was carried out using a 22G spinal needle and 4 drops of CSF were collected after clinical samples. The
specimens were put on ice, centrifuged at 1000 rpm at 4°C for 10 min and the supernatant was frozen at −80°C for batch analysis.

C5a measurement

Because C5a is rapidly cleaved to metabolite C5adesArg, we measured C5adesArg to estimate C5a levels in thawed CSF samples, using the C5a human ELISA kit (Hycult Biotech, Uden, The Netherlands), following the instructions of the manufacturer. The between batch coefficient of variation (CV) was 3%; the within batch CV was 3.4% and 2.6% across the two batches; and the lower limit of detection was 0.3 ng/ml.

Data analysis

Pearson’s Chi-squared test was used to compare the proportions. The distribution of C5a values was tested for equality of variance using Levene’s test, and group differences were investigated using Student’s t-test. GLM ANOVA was used to investigate possible confounding effects of systemic sepsis. Analyses were performed using SPSS 21.0 (SPSS Inc., Chicago, IL).

Results

Participants

CSF for C5a measurements was obtained from 20 term and 17 preterm infants (Table 1), and individual participant’s blood, CSF and diagnostic information were collected (Supplemental Table 1).

Cerebrospinal fluid analysis

There was no significant difference in the proportion of infants with CSF contaminated by blood defined as RBC > 1000 cells/mm³: 50% preterm versus 42% of controls, \( p = 0.73 \). The difference in proportion of infants with BSI in each group was not statistically significant (\( p = 0.33 \)), and there was no significant difference in CSF RBC count between infants with and without BSI (\( p = 0.559 \)).

No infant had meningitis. CSF white cell counts were within normal limits for age with the exception of one preterm infant (PT1) who had a marked CSF lymphocytosis without evidence of congenital infection, viral meningitis or neurometabolic disease. This individual had florid intraparenchymal echodensities on cranial ultrasound at the time of CSF sampling, and later MRI revealed evolution of these to cystic PVL. PT1’s CSF C5a concentration was 2.162 ng/ml, which was within the upper \( \times 1.5 \) IQR of values for the preterm group (Figure 1).

C5a in cerebrospinal fluid

C5a was present in the CSF of preterm and term infants, but values were higher in preterms compared with controls: mean CSF C5a concentration in preterm infants was 1.75 ng/ml (range 0.42–5.24) versus 0.98 ng/ml (range 0.37–2.48) in term infants, \( p = 0.006 \) (Figure 1).

When BSI at the time of sampling was included in the GLM ANOVA, the effect of prematurity remained statistically significant (\( F \)-statistic 9.3, \( p = 0.005 \)) and BSI was not significant (\( F \)-statistic 1.23, \( p = 0.28 \)).

Discussion

We demonstrated an increase in complement component C5a in the CSF of preterm infants compared with infants born at term. Our observations are consistent with the concept of a perinatal inflammatory response in CSF after preterm birth [6], and they provide a new potential therapeutic target for reducing preterm brain injury.

The data build upon studies in mice that implicate the C5a-C5aR pathway in the mechanism leading to increased glutamate release and foetal brain injury associated with intrauterine inflammation [5]. Further supportive evidence for a neurotoxic role of C5a in developmental brain injury comes from the observation that in utero exposure to malaria in mice alters brain development and outcome through a C5a-C5aR dependent pathway in a similar manner to the preterm birth mouse model [7].

The median age of sampling the preterm group was day 10 after birth and for the term group it was 2 d. Given the rapid turnover of CSF in the newborn (estimated to be 5 ml/kg/h), it is likely that C5a, which can be synthesised by all central nervous system cell types, is generated in the postnatal period
for both groups. Specific co-morbidities of preterm birth such as respiratory disease requiring mechanical ventilation and necrotising enterocolitis are associated with a systemic inflammatory response, and it is possible that these pathologies as well as blood stream infection sepsis (Table 1), could have contributed to an enhanced C5a response in CNS that was established over a longer period of time in the preterm group. This has clear implications for timing of potential therapies designed to target dysregulated C5a. Further studies with placental histopathology and cord blood sampling would be required to determine whether increased C5a is also a component of the foetal inflammatory response syndrome as suggested by pre-clinical studies.

CSF samples from neonates may contain red blood cells, which is most commonly due to contamination during sampling or intraventricular haemorrhage. There was no difference in the proportion of blood-stained taps (defined as RBC$>1000$/ml) between the preterm and term groups, and there was no significant difference in the RBC count of CSF samples taken from infants with and without systemic sepsis. Therefore, it is unlikely that sample contamination by blood explains the findings in CSF.

While some studies suggest physiological effects of C5a in foetal brain development [4], many others have demonstrated toxic effects of excessive C5a on neurons, glia and endothelial cells in models of neurodegeneration, CNS injury and CNS infection [2]. C5aR blockade augments the neuroprotective effects of hypothermia in in vitro systems of ischaemia [8], and pre-clinical studies show that inhibition of C5a generation with eculizumab or treatment with statins attenuates perinatal brain injury. These agents are already used in humans and they are safe for mother and foetus [9,10].

In conclusion, we provide evidence of a perinatal inflammatory response in CSF with a modest but statistically significant increase the concentration of complement split product C5a in preterm infants compared to term infants. C5a might be an important therapeutic target to reduce brain injury associated with preterm birth and further investigation is warranted.

Acknowledgements

The authors are grateful to the parents and carers who consented to take part in the study, and to clinical colleagues at the Neonatal Intensive Care Unit of the Royal Infirmary of Edinburgh for referring patients.

Declaration of interest

The authors declare that they have no competing interests.

This work was supported by the Theirworld (www.theirworld.org) and was undertaken in the MRC Centre for Reproductive Health which is funded by MRC Centre grant (MRC G1002033).

ORCID

James P. Boardman http://orcid.org/0000-0003-3904-8960
Rozalia Pataky http://orcid.org/0000-0002-7895-0263

References

1. Hagberg H, Mallard C, Ferriero DM, et al. The role of inflammation in perinatal brain injury. Nat Rev Neurol 2015;11: 192–208.
2. Woodruff TM, Ager RR, Tenner AJ, et al. The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med 2010;12:179–92.
3. Gasque P, Singhrao SK, Neal JW, et al. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 1997;150:31–41.
4. Benard M, Raoult E, Vaudry D, et al. Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum. Mol Immunol 2008;45:3767–74.

5. Pedroni SM, Gonzalez JM, Wade J, et al. Complement inhibition and statins prevent fetal brain cortical abnormalities in a mouse model of preterm birth. Biochim Biophys Acta 2013;1842:107–15.

6. Ellison VJ, Mocatta TJ, Winterbourn CC, et al. The relationship of CSF and plasma cytokine levels to cerebral white matter injury in the premature newborn. Pediatr Res 2005;57:282–6.

7. McDonald CR, Cahill LS, Ho KT, et al. Experimental malaria in pregnancy induces neurocognitive injury in uninfected offspring via a C5a-C5a receptor dependent pathway. PLoS Pathogens 2015;11:e1005140.

8. Thundyil J, Pavlovski D, Hsieh YH, et al. C5a receptor (CD88) inhibition improves hypothermia-induced neuroprotection in an in vitro ischemic model. Neuromol Med 2012;14:30–9.

9. Kelly RJ, Hochsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015;373:1032–9.

10. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. Bmj 2015;350:h1035.

Supplementary material available online